Tarsons Products Limited (TARSONS)

Healthcare · Healthcare Equipment & Supplies · NSE · Updated 23 July 2026

₹306.25 ↓ 19.93% (1Y)

🎯 Key Takeaways

Tarsons Products Limited is in a strategic reinvestment phase, transitioning from a high-margin legacy business to a capital-intensive bioprocessing and life sciences model, evidenced by significant capex in new facilities and expansion into international markets. Despite near-term margin pressure from inflation and depreciation, the company is targeting full operationalization of Panchla and Amta plants by H1FY27 to drive sustainable growth.
Revenue declined 3.6% QoQ to ₹96 in Q3FY25.
⚠️ Geopolitical exposure in the Middle East continues to impact export demand, with no immediate recovery expected.

Market Cap

₹1,101

P/E Ratio

36.9

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About TARSONS 📊 Interactive Charts

📖 The Story

Tarsons Products Limited is in a strategic reinvestment phase, transitioning from a high-margin legacy business to a capital-intensive bioprocessing and life sciences model, evidenced by significant capex in new facilities and expansion into international markets. Despite near-term margin pressure from inflation and depreciation, the company is targeting full operationalization of Panchla and Amta plants by H1FY27 to drive sustainable growth. The recent record revenue of ₹426 crores in FY26 reflects execution of this strategy, though profitability remains volatile due to macro headwinds and transition costs.

📰 What's Happening

In Q4FY26, Tarsons achieved record revenue of ₹426 crores (+7.7% YoY) and PAT of ₹112 crores (+21.5% YoY), driven by domestic demand despite a 13.4% export decline due to Middle East tensions. Management highlighted full commissioning of Panchla and Amta facilities by H1FY27 to accelerate growth, supported by strategic capex in bioprocessing and cell culture. The company also completed the second tranche of its EUR 3 million equity investment in its Singapore subsidiary to fund loan repayments and operations, underscoring global expansion. A key leadership change occurred with the resignation of HR Head Subhra Shankar Bose effective June 15, 2026, raising succession concerns.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q3FY22	Q4FY22	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	71	85	62	106	85	99	96
Operating Profit	36	47	26	34	22	34	30
OPM %	46.9%	52.2%	37.0%	28.6%	22.1%	25.5%	31.0%
Net Profit	21	29	10	10	4	10	5
EPS	₹4.14	₹5.69	₹1.87	₹1.94	₹0.75	₹1.93	₹0.99

Revenue has shown consistent growth over the past two years, rising from ₹62 crores in Q3FY22 to ₹426 crores in FY26, reflecting successful capacity expansion and market penetration. However, profitability has been uneven — OPM declined from a peak of 52.2% in Q4FY22 to 28.3% in Q4FY26 due to depreciation, finance costs, and raw material inflation. Despite this, EBITDA reached ₹110.1 crores with a 28.3% margin in Q4FY26, indicating underlying operational resilience. The PAT growth of 21.5% YoY in FY26 was supported by adjusted cash metrics, even as reported PAT dipped in earlier quarters due to transition-related expenses.

🔮 Management Outlook & What's Next

Management has explicitly stated that full operations at Panchla and Amta facilities are expected in H1FY27, which will accelerate growth and improve margins. They emphasized resilience amid supply constraints and pricing pressures, attributing performance to strategic capex in bioprocessing and cell culture. The company is focused on scaling domestic demand while navigating export volatility, particularly in the Middle East. No formal long-term guidance was provided, but capital allocation remains tied to facility ramp-up and international expansion.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Healthcare Equipment & Supplies

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Poly Medicure Limited	15,193	46.4	—	—	—
Fischer Medical Ventures Limited	2,261	59.0	—	—	—
Laxmi Dental Limited	1,105	57.2	—	—	—
Tarsons Products Limited	1,101	36.9	—	—	—
Fabtech Technologies Limited	681	—	—	—	—
Nureca Limited	260	-47.3	—	—	—

🔗 Peer Stock Analyses

POLYMED FISCHER LAXMIDENTL FABTECH NURECA

⚠️ Risk Factors

1. Geopolitical exposure in the Middle East continues to impact export demand, with no immediate recovery expected. 2. Margin compression from raw material inflation and transition-related depreciation poses near-term profitability risks. 3. Leadership turnover in HR raises concerns about execution stability during a critical expansion phase. 4. High capital expenditure requirements may strain liquidity if operational ramp-up at new facilities is delayed.

📋 Recent Filings

🧠 Analyst's Read

Tarsons is executing a high-stakes transition from a mature, high-margin equipment business to a growth-oriented bioprocessing model, requiring flawless execution and macro stability. Investors should monitor the H1FY27 commissioning timeline, export recovery trends, and margin trajectory as key inflection points.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on TARSONS

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-23.

📡 Get AI alerts when TARSONS files new disclosures

Track TARSONS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track TARSONS — Free

Free account · 2 AI queries/day